Agonist and antagonist properties of buprenorphine, a new antinociceptive agent.
about
Mixed agonist-antagonist opiates and physical dependenceBuprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically activeP-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociceptionBuprenorphine: a unique drug with complex pharmacologyEffect of rifampin and nelfinavir on the metabolism of methadone and buprenorphine in primary cultures of human hepatocytesHS-599: a novel long acting opioid analgesic does not induce place-preference in ratsThe nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medicationsRole of active metabolites in the use of opioidsA double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphineChronic treatment with novel brain-penetrating selective NOP receptor agonist MT-7716 reduces alcohol drinking and seeking in the ratPharmacological mechanisms underlying the antinociceptive and tolerance effects of the 6,14-bridged oripavine compound 030418The cannabinoid agonist HU-210: pseudo-irreversible discriminative stimulus effects in rhesus monkeys.Practical considerations for the clinical use of buprenorphine.Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals.Enhancement of tolerance development to morphine in rats prenatally exposed to morphine, methadone, and buprenorphineAcute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers.Determination of receptors that mediate opiate side effects in the mouse.Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats.Opioid antagonist effects of dezocine in opioid-dependent humans.Transdermal buprenorphine - a critical appraisal of its role in pain management.BU08073 a buprenorphine analogue with partial agonist activity at μ-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice.Opioid dependence treatment, including buprenorphine/naloxone.A role for the mu opioid receptor in the antidepressant effects of buprenorphine.Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor systemThe subjective, reinforcing, and analgesic effects of oxycodone in patients with chronic, non-malignant pain who are maintained on sublingual buprenorphine/naloxone.The first universal opioid ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028): characterization of the in vitro profile and in vivo behavioral effects in mousOpioids and the treatment of chronic pain: controversies, current status, and future directions.μ-Opioid receptor activation and noradrenaline transport inhibition by tapentadol in rat single locus coeruleus neuronsEffects of μ-opioid receptor agonists in assays of acute pain-stimulated and pain-depressed behavior in male rats: role of μ-agonist efficacy and noxious stimulus intensity.Refinement of analgesia following thoracotomy and experimental myocardial infarction using the Mouse Grimace Scale.A statistical experimental design approach to evaluate the influence of various penetration enhancers on transdermal drug delivery of buprenorphineThe animal pharmacology of buprenorphine, an oripavine analgesic agent.Enhancement of a nociceptive reaction by opioid antagonists in mice.Gender differences in pharmacokinetics of maintenance dosed buprenorphine.Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphineBuprenorphine differentially alters opioid receptor adaptation in rat brain regions.Developmental responses to opioids reveals a lack of effect on stress-induced corticosterone levels in neonatal rats.Investigation of the antinociceptive activity of buprenorphine in sheep.Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.Assessment of an Orofacial Operant Pain Assay as a Preclinical Tool for Evaluating Analgesic Efficacy in Rodents
P2860
Q24547874-5C3E8990-6F67-4EBE-82E5-40BE79056848Q24629014-E7A762F0-7B4A-40C5-9D33-FCA5DB907E74Q24631289-38D25A58-6E1D-471E-9037-C4A4063DFA71Q24642980-E563AA98-04B9-4B4E-B527-F69CCB14826AQ24649164-0D8D8037-6408-4155-BAB9-25B4B82D4373Q24673536-CC179039-BC18-4F1B-A379-0A596EF06A1AQ28297686-CB72E19E-6343-4814-9324-B119939DAEF6Q28298981-4BF0D695-7713-433D-9408-54FA9847602FQ30570686-A36027AC-3870-4956-9B0F-51C4A5682235Q30595729-EDC4E3DC-B55F-4392-8592-C672EEDC20EFQ33566172-3BD6A312-77BC-46DA-88A9-C289A4889621Q33698310-474D44B7-7A9E-42E4-ABA2-249F780ED2E6Q33774853-A5681AF7-CCDC-4551-8EB1-F55DD719D291Q33837582-720ADCB4-B3BA-4B18-AE03-04BB071E70E8Q33934135-7E678DDE-0218-4B18-9722-3A22903064B4Q34138291-65016323-8EA9-474D-BAE7-8C94BDC798C3Q34255212-D4A89C29-AD66-4CFD-A2A1-B3F27CC24F4CQ34320180-1135ABDD-7F06-4AAE-A571-998002C82CAEQ34398867-AADE3EAD-5F2D-4E4E-BA0C-6AD2FBB94029Q34418193-09F5A80A-6472-4F3B-BF66-EFEC8D4398E8Q34423181-B485D90C-CEAA-4450-AEDF-B39B78819E4EQ34533873-3A61ECC9-44E2-45F2-9D6F-160721D79767Q34544184-ABE0722A-FE08-4DDA-A190-A8F079F16D3CQ34561447-D7E75C6D-639B-4B5F-BF9E-541784E63868Q34661770-E9EAA715-8906-4901-BF18-3FA66708F5A6Q34702273-A43C1B24-9578-40A7-8AA1-0E9CF5516B38Q34846394-5F9458FA-DBF7-4659-995E-5ABEEE6CAE1CQ34939720-EAAE98EE-6EEF-40AF-9B07-F833FA2A2010Q34946659-282B1728-56F1-40A1-8D40-86F681C2CA01Q35120197-9E0B125D-BA82-42C7-ACF7-4664D3258E1BQ35143698-01030A32-9E2B-4BFD-A09E-EA9829E7AB86Q35176474-141E6998-BDB2-4228-881D-4EE9910FAA52Q35177657-366CAF52-18B1-4DE3-89F8-D59BB9430A9BQ35184385-55F1D85B-7748-4D85-AA9F-1542227936A0Q35284997-ED3D7BD6-F2A6-4680-BDED-58B433CEBBD3Q35653140-315C6936-AB4A-4160-A92D-46902EFDC1B1Q35754701-999DDB34-1884-4B23-B3E7-0EE9F56423E5Q35755099-7836F55B-6AED-48B0-9808-15D0F91FDA4FQ35863900-6C0773DD-0238-46AD-AE16-70207A2B67C5Q35906905-9807BFE8-EF2D-4EDC-907B-9E77208A5051
P2860
Agonist and antagonist properties of buprenorphine, a new antinociceptive agent.
description
1977 nî lūn-bûn
@nan
1977 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1977 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1977年の論文
@ja
1977年論文
@yue
1977年論文
@zh-hant
1977年論文
@zh-hk
1977年論文
@zh-mo
1977年論文
@zh-tw
1977年论文
@wuu
name
Agonist and antagonist properties of buprenorphine, a new antinociceptive agent.
@ast
Agonist and antagonist properties of buprenorphine, a new antinociceptive agent.
@en
type
label
Agonist and antagonist properties of buprenorphine, a new antinociceptive agent.
@ast
Agonist and antagonist properties of buprenorphine, a new antinociceptive agent.
@en
prefLabel
Agonist and antagonist properties of buprenorphine, a new antinociceptive agent.
@ast
Agonist and antagonist properties of buprenorphine, a new antinociceptive agent.
@en
P2093
P2860
P1476
Agonist and antagonist properties of buprenorphine, a new antinociceptive agent.
@en
P2093
P2860
P304
P356
10.1111/J.1476-5381.1977.TB07532.X
P407
P577
1977-08-01T00:00:00Z